Sanofi Pasteur, CureVac ink wide-ranging vaccine deal

Sanofi Pasteur and Germany's CureVac have signed a €150 million deal to develop and apply the latter's RNActive technology platform to the development of vaccines against several infectious diseases. And in a related deal, CureVac, Sanofi and France's In-Cell-Art will undertake a $33 million DARPA research program to identify and create a universal vaccine technology platform for infectious diseases. 

Over the next four years, CureVac, Sanofi and In-Cell-Art will advance key aspects of the RNActive technology platform and evaluate several vaccine candidates in a number of disease models. In-Cell-Art is developing nano-carriers for macromolecular drugs which allows them to cross the cell barrier efficiently and safely, according to a release. 

In a parallel agreement, Sanofi could give CureVac up to €101.5 million ($137.1 million) in milestones in return for the rights to several pre-defined pathogens. That number could grow to €150.5 million ($203.2 million) is Sanofi is able to develop a new therapeutic or preventative vaccine with a single pathogen.

"We are very pleased that Sanofi Pasteur has recognized the full potential of our RNActive technology platform for the development of vaccines particularly for infectious diseases. This multi-year collaboration will allow us to significantly strengthen our technology platform and to scale it up for commercial vaccination purposes," says Ingmar Hoerr, CEO of CureVac.

- here's the press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.